USD 2.75
(0.37%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 6.13 Million USD | -19.39% |
2022 | 7.61 Million USD | 282.49% |
2021 | 1.99 Million USD | -0.45% |
2020 | 2 Million USD | 139.98% |
2019 | 833.52 Thousand USD | -30.67% |
2018 | 1.2 Million USD | 44.71% |
2017 | 830.84 Thousand USD | 203.11% |
2016 | 274.1 Thousand USD | -78.42% |
2015 | 1.27 Million USD | 139.23% |
2014 | 531 Thousand USD | 1263.29% |
2013 | 38.95 Thousand USD | -39.49% |
2012 | 64.36 Thousand USD | 1774.4% |
2011 | 3434.00 USD | -69.89% |
2010 | 11.4 Thousand USD | -20.33% |
2009 | 14.31 Thousand USD | -37.05% |
2008 | 22.73 Thousand USD | 1415.93% |
2007 | 1500.00 USD | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q1 | 7.07 Million USD | 15.3% |
2024 Q2 | 5.81 Million USD | -17.91% |
2023 Q1 | 7.56 Million USD | -0.71% |
2023 Q2 | 5.3 Million USD | -29.91% |
2023 FY | 6.13 Million USD | -19.39% |
2023 Q4 | 6.13 Million USD | 7.96% |
2023 Q3 | 5.68 Million USD | 7.29% |
2022 Q2 | 104.68 Thousand USD | 9.92% |
2022 FY | 7.61 Million USD | 282.49% |
2022 Q3 | 480.2 Thousand USD | 358.72% |
2022 Q1 | 95.23 Thousand USD | -95.22% |
2022 Q4 | 7.61 Million USD | 1486.03% |
2021 FY | 1.99 Million USD | -0.45% |
2021 Q1 | 2.94 Million USD | 47.12% |
2021 Q3 | 3.67 Million USD | 36.66% |
2021 Q2 | 2.68 Million USD | -8.6% |
2021 Q4 | 1.99 Million USD | -45.83% |
2020 Q1 | 772.29 Thousand USD | -7.35% |
2020 FY | 2 Million USD | 139.98% |
2020 Q3 | 1.1 Million USD | 47.5% |
2020 Q4 | 2 Million USD | 80.96% |
2020 Q2 | 749.43 Thousand USD | -2.96% |
2019 FY | 833.52 Thousand USD | -30.67% |
2019 Q3 | 889.19 Thousand USD | -3.94% |
2019 Q2 | 925.69 Thousand USD | -36.54% |
2019 Q1 | 1.45 Million USD | 21.33% |
2019 Q4 | 833.52 Thousand USD | -6.26% |
2018 Q2 | 1.44 Million USD | -3.76% |
2018 Q3 | 1.05 Million USD | -26.74% |
2018 FY | 1.2 Million USD | 44.71% |
2018 Q1 | 1.5 Million USD | 80.9% |
2018 Q4 | 1.2 Million USD | 13.46% |
2017 Q1 | 284.45 Thousand USD | 3.78% |
2017 Q4 | 830.84 Thousand USD | 36.23% |
2017 Q2 | 780.62 Thousand USD | 174.43% |
2017 FY | 830.84 Thousand USD | 203.11% |
2017 Q3 | 609.86 Thousand USD | -21.87% |
2016 Q1 | 1.18 Million USD | -6.64% |
2016 FY | 274.1 Thousand USD | -78.42% |
2016 Q4 | 274.1 Thousand USD | -0.93% |
2016 Q3 | 276.68 Thousand USD | -77.21% |
2016 Q2 | 1.21 Million USD | 2.35% |
2015 FY | 1.27 Million USD | 139.23% |
2015 Q4 | 1.27 Million USD | 170.53% |
2015 Q2 | 436.06 Thousand USD | 14.99% |
2015 Q3 | 469.56 Thousand USD | 7.68% |
2015 Q1 | 379.23 Thousand USD | -28.58% |
2014 Q2 | 382.27 Thousand USD | 106.59% |
2014 FY | 531 Thousand USD | 1263.29% |
2014 Q1 | 185.03 Thousand USD | 375.06% |
2014 Q4 | 531 Thousand USD | 16.28% |
2014 Q3 | 456.64 Thousand USD | 19.45% |
2013 Q4 | 38.95 Thousand USD | 65.54% |
2013 Q3 | 23.52 Thousand USD | 60.24% |
2013 Q2 | 14.68 Thousand USD | -34.31% |
2013 Q1 | 22.35 Thousand USD | -65.27% |
2013 FY | 38.95 Thousand USD | -39.49% |
2012 Q4 | 64.36 Thousand USD | 333.27% |
2012 Q1 | 20.51 Thousand USD | 497.5% |
2012 Q2 | 29.39 Thousand USD | 43.25% |
2012 Q3 | 14.85 Thousand USD | -49.46% |
2012 FY | 64.36 Thousand USD | 1774.4% |
2011 Q1 | 330.00 USD | -97.11% |
2011 Q3 | 4545.00 USD | 0.0% |
2011 FY | 3434.00 USD | -69.89% |
2011 Q4 | 3434.00 USD | -24.44% |
2011 Q2 | - USD | -100.0% |
2010 Q3 | 23.78 Thousand USD | 42.42% |
2010 Q4 | 11.4 Thousand USD | -52.05% |
2010 Q2 | 16.69 Thousand USD | 4.44% |
2010 FY | 11.4 Thousand USD | -20.33% |
2010 Q1 | 15.98 Thousand USD | 0.0% |
2009 FY | 14.31 Thousand USD | -37.05% |
2009 Q3 | - USD | -100.0% |
2009 Q2 | 43.36 Thousand USD | 25.34% |
2009 Q1 | 34.59 Thousand USD | 18.03% |
2008 Q1 | 17.37 Thousand USD | 584.4% |
2008 FY | 22.73 Thousand USD | 1415.93% |
2008 Q3 | 26.67 Thousand USD | 17.33% |
2008 Q4 | 29.31 Thousand USD | 9.87% |
2008 Q2 | 22.73 Thousand USD | 30.91% |
2007 Q2 | - USD | 0.0% |
2007 Q3 | 3288.00 USD | 0.0% |
2007 FY | 1500.00 USD | 0.0% |
2007 Q4 | 2538.00 USD | -22.81% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Theratechnologies Inc. | 98.63 Million USD | 93.776% |
Harrow Health, Inc. | 241.75 Million USD | 97.46% |
Dynavax Technologies Corporation | 375.02 Million USD | 98.363% |
Biofrontera Inc. | 23.13 Million USD | 73.466% |
Cronos Group Inc. | 43.73 Million USD | 85.962% |
Sonoma Pharmaceuticals, Inc. | 8.75 Million USD | 29.881% |
Ironwood Pharmaceuticals, Inc. | 817.36 Million USD | 99.249% |
Kala Pharmaceuticals, Inc. | 48.44 Million USD | 87.327% |
RedHill Biopharma Ltd. | 20.97 Million USD | 70.733% |
Cumberland Pharmaceuticals Inc. | 52.51 Million USD | 88.309% |
Radius Health, Inc. | 804.29 Million USD | 99.237% |
Universe Pharmaceuticals INC | 13.75 Million USD | 55.362% |
DURECT Corporation | 30.4 Million USD | 79.808% |
ProPhase Labs, Inc. | 42.54 Million USD | 85.569% |
Safety Shot Inc | 3.89 Million USD | -57.747% |
Phibro Animal Health Corporation | 725.54 Million USD | 99.154% |
China SXT Pharmaceuticals, Inc. | 9.19 Million USD | 33.241% |
Alvotech | 1.88 Billion USD | 99.674% |
Assertio Holdings, Inc. | 148.41 Million USD | 95.863% |
Supernus Pharmaceuticals, Inc. | 487.46 Million USD | 98.74% |
Rockwell Medical, Inc. | 30.88 Million USD | 80.119% |
Procaps Group S.A. | 462.06 Million USD | 98.671% |
Intra-Cellular Therapies, Inc. | 136.87 Million USD | 95.514% |
SCYNEXIS, Inc. | 55.45 Million USD | 88.928% |
Aytu BioPharma, Inc. | 90.37 Million USD | 93.207% |
Viatris Inc. | 27.21 Billion USD | 99.977% |
OptiNose, Inc. | 194.33 Million USD | 96.841% |
SIGA Technologies, Inc. | 57.97 Million USD | 89.41% |
Tilray Brands, Inc. | 892.11 Million USD | 99.312% |
PetIQ, Inc. | 645.22 Million USD | 99.048% |
Sunshine Biopharma, Inc. | 6.13 Million USD | 0.0% |
Neurocrine Biosciences, Inc. | 1.01 Billion USD | 99.398% |
Guardion Health Sciences, Inc. | 3.77 Million USD | -62.762% |
Alimera Sciences, Inc. | 107.35 Million USD | 94.281% |
Collegium Pharmaceutical, Inc. | 947.87 Million USD | 99.352% |
Silver Spike Investment Corp. | 3 Million USD | -103.985% |
Shuttle Pharmaceuticals Holdings, Inc. | 1.89 Million USD | -223.825% |
Organogenesis Holdings Inc. | 181.36 Million USD | 96.615% |
Journey Medical Corporation | 56.49 Million USD | 89.133% |
Petros Pharmaceuticals, Inc. | 21.31 Million USD | 71.197% |
Alpha Teknova, Inc. | 38.55 Million USD | 84.074% |
Clever Leaves Holdings Inc. | 7.02 Million USD | 12.616% |
Lifecore Biomedical, Inc. | 219.8 Million USD | 97.207% |
PainReform Ltd. | 2.69 Million USD | -128.153% |
Cosmos Health Inc. | 30.25 Million USD | 79.705% |
Avadel Pharmaceuticals plc | 173.38 Million USD | 96.459% |
TherapeuticsMD, Inc. | 14.02 Million USD | 56.215% |
Embecta Corp. | 2.03 Billion USD | 99.698% |
Regencell Bioscience Holdings Limited | 219.51 Thousand USD | -2696.931% |
Talphera, Inc. | 6.29 Million USD | 2.391% |
Pacira BioSciences, Inc. | 704.25 Million USD | 99.128% |
Incannex Healthcare Limited | 5.83 Million USD | -5.31% |
Cyclo Therapeutics, Inc. | 8.49 Million USD | 27.689% |
Shineco, Inc. | 47.6 Million USD | 87.102% |
Procaps Group, S.A. | 462.06 Million USD | 98.671% |
ANI Pharmaceuticals, Inc. | 471.67 Million USD | 98.698% |
Aquestive Therapeutics, Inc. | 163.9 Million USD | 96.254% |
Lantheus Holdings, Inc. | 835.25 Million USD | 99.265% |
Alvotech | 1.88 Billion USD | 99.674% |
Hempacco Co., Inc. | 18.82 Million USD | 67.381% |
Eagle Pharmaceuticals, Inc. | 172.6 Million USD | 96.443% |
Bright Green Corporation | 6.43 Million USD | 4.636% |
Esperion Therapeutics, Inc. | 660.79 Million USD | 99.071% |
Kamada Ltd. | 109.96 Million USD | 94.417% |
Indivior PLC | 1.95 Billion USD | 99.685% |
Evoke Pharma, Inc. | 9.64 Million USD | 36.365% |
Flora Growth Corp. | 17.22 Million USD | 64.35% |
Cyclo Therapeutics, Inc. | 8.49 Million USD | 27.689% |
Evolus, Inc. | 209.68 Million USD | 97.072% |
HUTCHMED (China) Limited | 536.38 Million USD | 98.855% |
Amphastar Pharmaceuticals, Inc. | 873.49 Million USD | 99.297% |
Akanda Corp. | 12.66 Million USD | 51.538% |